FDA updates its guidance, potentially enabling broader adoption of LLM-based clinical decision support software in radiology.
Key Details
- 1FDA released updated guidance on regulating clinical decision-support (CDS) software as a medical device in January 2024.
- 2The new guidance clarifies that certain LLM and CDS tools that do not directly analyze images may be exempt from device regulation if they meet four specific criteria.
- 3Previously, tools generating diagnostic text recommendations or risk predictions were typically regulated as medical devices.
- 4The updated interpretation may open opportunities for more LLM-based applications to assist radiologists without requiring full FDA device approval, provided clinicians retain review authority.
- 5Image-analyzing AI (such as CAD or denoising tools) remains regulated as medical devices.
Why It Matters
This policy shift could accelerate development and clinical adoption of text-based AI assistants and reporting tools in radiology, reducing regulatory barriers. Clarity from the FDA also helps innovators and healthcare providers assess which AI-driven software must undergo formal device review.
Source
AuntMinnie
Related News
•Radiology Business
NCCN Endorses AI Risk Tools for Breast Cancer Screening
NCCN's 2026 guidelines recommend routine integration of AI-based 5-year breast cancer risk prediction from mammograms.
•Radiology Business
ACR Expands Resources for Radiology Practices to Assess Imaging AI
The ACR is offering new tools to help radiology practices evaluate and monitor imaging AI algorithms.
•HealthExec
EFF Sues CMS For Transparency on AI-Powered Medicare Prior Authorization
EFF has sued CMS to compel disclosure about the WISeR pilot deploying AI for Medicare prior authorization.